Drug intelligence / Profile preview

vespula spp. venom allergens

Development stage: Unknown
Lead developer: ALK Abelló
Modality: Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Alutard SQ 802 Vespula spp. is a subcutaneous allergen immunotherapy (SCIT) product developed by ALK (ALK-Abelló) for the treatment of IgE-mediated wasp venom allergy. It consists of a standardized extract of venom from multiple *Vespula* species, including *V. germanica*, *V. alascensis*, *V. maculifrons*, *V. flavopilosa*, *V. pensylvanica*, and *V. squamosa*. The allergens are adsorbed onto aluminium hydroxide, which serves as an adjuvant to create a depot effect, allowing for slow release and prolonged immune stimulation. The primary mechanism of action involves inducing immunological tolerance by shifting the immune response from a Th2-mediated allergic profile to a Th1/Treg-mediated regulatory profile, characterized by a decrease in specific IgE levels and an increase in protective IgG4 antibodies. This desensitization process significantly reduces the risk of systemic anaphylactic reactions upon subsequent stings. It is currently used in various clinical protocols, including accelerated outpatient regimens, to achieve maintenance dosing and clinical efficacy more rapidly.

Brand names: Alutard SQ 802 Vespula spp.Alutard SQAlutard SQ Wasp
Other names: Vespula spp. venom extractWasp venom immunotherapy

Targets

Hyaluronan and related glycosaminoglycans (HA and GAGs)

Beyond the preview

Go deeper on vespula spp. venom allergens.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vespula spp. venom allergens.

Explore the full profile